221 related articles for article (PubMed ID: 27465068)
1. Complement C3 is expressed by mast cells in cutaneous vasculitis and is degraded by chymase.
Lipitsä T; Naukkarinen A; Laitala J; Harvima IT
Arch Dermatol Res; 2016 Oct; 308(8):575-84. PubMed ID: 27465068
[TBL] [Abstract][Full Text] [Related]
2. Mast cell tryptase and chymase in the progress of cutaneous vasculitis.
Lipitsä T; Naukkarinen A; Harvima IT
Arch Dermatol Res; 2015 Dec; 307(10):917-24. PubMed ID: 26498154
[TBL] [Abstract][Full Text] [Related]
3. Mast cell chymase degrades fibrinogen and fibrin.
Lipitsä T; Siiskonen H; Naukkarinen A; Harvima IT
Br J Dermatol; 2019 Aug; 181(2):296-303. PubMed ID: 30561017
[TBL] [Abstract][Full Text] [Related]
4. Degradation of human anaphylatoxin C3a by rat peritoneal mast cells: a role for the secretory granule enzyme chymase and heparin proteoglycan.
Gervasoni JE; Conrad DH; Hugli TE; Schwartz LB; Ruddy S
J Immunol; 1986 Jan; 136(1):285-92. PubMed ID: 3510005
[TBL] [Abstract][Full Text] [Related]
5. The increase in tryptase- and chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma.
Diaconu NC; Kaminska R; Naukkarinen A; Harvima RJ; Harvima IT
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):908-15. PubMed ID: 17658999
[TBL] [Abstract][Full Text] [Related]
6. Alterations in mast cell proteinases and protease inhibitors in the progress of cutaneous herpes zoster infection.
Kaminska R; Harvima IT; Naukkarinen A; Nilsson G; Horsmanheimo M
J Pathol; 1996 Dec; 180(4):434-40. PubMed ID: 9014866
[TBL] [Abstract][Full Text] [Related]
7. Mast cell lines HMC-1 and LAD2 in comparison with mature human skin mast cells--drastically reduced levels of tryptase and chymase in mast cell lines.
Guhl S; Babina M; Neou A; Zuberbier T; Artuc M
Exp Dermatol; 2010 Sep; 19(9):845-7. PubMed ID: 20545757
[TBL] [Abstract][Full Text] [Related]
8. Mast cell chymase in experimentally induced psoriasis.
Suttle MM; Harvima IT
J Dermatol; 2016 Jun; 43(6):693-6. PubMed ID: 26703925
[TBL] [Abstract][Full Text] [Related]
9. Mast cell tryptase and chymase in chronic leg ulcers: chymase is potentially destructive to epithelium and is controlled by proteinase inhibitors.
Huttunen M; Harvima IT
Br J Dermatol; 2005 Jun; 152(6):1149-60. PubMed ID: 15948975
[TBL] [Abstract][Full Text] [Related]
10. The production of collagen and the activity of mast-cell chymase increase in human skin after irradiation therapy.
Riekki R; Harvima IT; Jukkola A; Risteli J; Oikarinen A
Exp Dermatol; 2004 Jun; 13(6):364-71. PubMed ID: 15186323
[TBL] [Abstract][Full Text] [Related]
11. Mast cell tryptase and chymase in developing and mature psoriatic lesions.
Harvima IT; Naukkarinen A; Paukkonen K; Harvima RJ; Aalto ML; Schwartz LB; Horsmanheimo M
Arch Dermatol Res; 1993; 285(4):184-92. PubMed ID: 8342961
[TBL] [Abstract][Full Text] [Related]
12. Mast cell chymase is present in uterine cervical carcinoma and it detaches viable and growing cervical squamous carcinoma cells from substratum in vitro.
Diaconu NC; Rummukainen J; Naukkarinen A; Mättö M; Harvima RJ; Pelkonen J; Harvima IT
Arch Dermatol Res; 2011 Sep; 303(7):499-512. PubMed ID: 21274549
[TBL] [Abstract][Full Text] [Related]
13. The release of histamine is associated with the inactivation of mast cell chymase during immediate allergic wheal reaction in the skin.
Saarinen JV; Harvima RJ; Naukkarinen A; Horsmanheimo M; Harvima IT
Clin Exp Allergy; 2001 Apr; 31(4):593-601. PubMed ID: 11359428
[TBL] [Abstract][Full Text] [Related]
14. Decrease in chymase activity is associated with increase in IL-6 expression in mast cells in atopic dermatitis.
Ilves T; Harvima IT
Acta Derm Venereol; 2015 Apr; 95(4):411-6. PubMed ID: 25270893
[TBL] [Abstract][Full Text] [Related]
15. Mast cells in systemic and cutaneous lupus erythematosus.
Kaczmarczyk-Sekuła K; Dyduch G; Kostański M; Wielowieyska-Szybińska D; Szpor J; Białas M; Okoń K
Pol J Pathol; 2015 Dec; 66(4):397-402. PubMed ID: 27003772
[TBL] [Abstract][Full Text] [Related]
16. Decreased chymase activity is associated with increased levels of protease inhibitors in mast cells of psoriatic lesions.
Harvima IT; Haapanen L; Ackermann L; Naukkarinen A; Harvima RJ; Horsmanheimo M
Acta Derm Venereol; 1999 Mar; 79(2):98-104. PubMed ID: 10228625
[TBL] [Abstract][Full Text] [Related]
17. Mast cells in cutaneous allergic vasculitis: a case report.
Inamura H; Igarashi Y; Kashiwase Y; Morioka J; Suzuki K; Kurosawa M
Allergol Int; 2006 Sep; 55(3):343-5. PubMed ID: 17075278
[TBL] [Abstract][Full Text] [Related]
18. Mast cells in developing subepidermal bullous diseases: emphasis on tryptase, chymase and protease inhibitors.
Kaminska R; Naukkarinen A; Glinski W; Horsmanheimo M; Harvima IT
Acta Derm Venereol; 1999 Sep; 79(5):351-5. PubMed ID: 10494709
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-4-positive mast cells are highly associated with the extent of immediate allergic wheal reaction in the skin.
Saarinen JV; Harvima RJ; Naukkarinen A; Horsmanheimo M; Harvima IT
Allergy; 2001 Jan; 56(1):58-64. PubMed ID: 11167353
[TBL] [Abstract][Full Text] [Related]
20. Induction of C3 and CCL2 by C3a in keratinocytes: a novel autocrine amplification loop of inflammatory skin reactions.
Purwar R; Wittmann M; Zwirner J; Oppermann M; Kracht M; Dittrich-Breiholz O; Gutzmer R; Werfel T
J Immunol; 2006 Oct; 177(7):4444-50. PubMed ID: 16982879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
